Zika virus: FAQ available

The mosquito-borne Zika virus has been much in the news of late, with reports pouring in on several new cases in the U.S. and, perhaps most alarmingly, a connection to infant brain defects in Brazil.

On Jan. 21, the Washington Post put up an informative rundown of frequently asked questions fleshing out the basics of the infection, CDC guidelines and what in the world is going on in Brazil (where the total case count has now topped 1 million).

Click here for the FAQ.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.